Herbal Formula JI-017 Shows Anti-Inflammatory Promise in Sepsis Model

Sepsis remains one of the most formidable challenges in modern medicine, a condition in which the body’s own immune response turns against it, unleashing a storm of inflammatory molecules that can drive multiple organs toward failure. Despite decades of research and steady advances in supportive care, clinicians still lack pharmacological tools that directly and safely rein in the runaway inflammation that defines the syndrome. Now, a team of researchers at Kyung Hee University in Seoul reports that a traditional multi-herbal formulation known as JI-017, previously studied mainly for its anticancer properties, dampened inflammatory responses in macrophages and was associated with improved survival in a mouse model of acute endotoxemia. The study, published in Molecular Biology Reports, offers an intriguing glimpse of how carefully balanced herbal combinations might modulate inflammation without shutting down host defense altogether.

JI-017 is not a single molecule but a blend of extracts from three medicinal plants: Angelica gigas, Aconitum carmichaeli Debeaux, and Zingiber officinale Roscoe, combined in a precise 2:1:1 ratio. Each component has a long history in traditional Korean medicine, and earlier work by some of the same researchers had shown that the formulation could suppress STAT3 signaling and trigger endoplasmic reticulum stress-mediated apoptosis in hepatocellular carcinoma models. But inflammation and cancer biology share deep molecular roots, and the team suspected that the same multi-component architecture that made JI-017 interesting in oncology might also make it relevant to sepsis, a disease in which no single drug target has proved sufficient.

To explore that hypothesis systematically, the investigators began in silico. They mined the GeneCards and NCBI Gene databases using the names of the three herbs and twelve of their signature compounds, including decursin, nodakenin, aconitine, hypaconitine, 6-gingerol, and 6-shogaol. After standardizing gene symbols to official HGNC nomenclature and removing duplicates, they assembled a set of 233 genes associated with JI-017. Crossing this list against 3,622 sepsis-related genes curated from GeneCards revealed 91 shared genes, a substantial overlap that suggested the formulation’s molecular targets intersect meaningfully with sepsis biology. Protein-protein interaction analysis using the STRING database showed that the JI-017-associated genes formed a densely connected network of 151 nodes and 1,952 edges, indicating that the formulation’s putative targets do not operate in isolation but cluster within coordinated functional modules.

The prioritization analysis sharpened the picture further. When the researchers ranked all sepsis-related genes by their GeneCards relevance scores and selected the top 10 percent as an exploratory subset, 42 of the 91 shared genes fell within that high-priority group. Mapping these genes onto the Kyoto Encyclopedia of Genes and Genomes highlighted their concentration in the Toll-like receptor signaling pathway, the canonical route by which immune cells detect bacterial lipopolysaccharide, or LPS, and launch the inflammatory cascades that include the MAPK and NF-κB pathways. This computational groundwork pointed the team toward macrophages, the sentinels of innate immunity, as the logical cellular testing ground.

In the laboratory, the researchers turned to RAW 264.7 murine macrophages, a workhorse cell line for inflammation research. Safety came first: a WST-8 viability assay across a double-fold dilution series from 100 to 0.7813 micrograms per milliliter showed that concentrations of 25 micrograms per milliliter and above significantly reduced cell viability, so subsequent anti-inflammatory experiments used lower, non-toxic doses. When macrophages were stimulated with LPS and co-treated with JI-017 at concentrations from 10 down to 1.25 micrograms per milliliter, nitric oxide production, normalized to cell viability, fell in a dose-dependent manner, with the three highest concentrations all reaching statistical significance at p less than 0.0001 compared with LPS alone.

The cytokine data were equally striking. Enzyme-linked immunosorbent assays of culture supernatants revealed that JI-017 at 10 micrograms per milliliter significantly reduced secretion of TNF-α, IL-1β, IL-6, and, notably, the anti-inflammatory cytokine IL-10, alongside the chemokines CXCL-1 and CXCL-2. Quantitative real-time PCR confirmed that the suppression occurred at the transcript level, with mRNA levels of TNF-α, IL-1β, IL-6, inducible nitric oxide synthase, cyclooxygenase-2, IL-10, CXCL-1, and CXCL-2 all significantly decreased in the treated group. Western blotting independently verified reduced protein expression of iNOS and COX-2, the two enzymes most responsible for producing nitric oxide and inflammatory prostaglandins during macrophage activation. The authors interpret the simultaneous reduction of pro- and anti-inflammatory cytokines as evidence of a general dampening of LPS-driven transcriptional activation rather than a specific polarization of the immune response toward any particular state.

One of the study’s most technically interesting findings, however, was what the researchers did not observe. Given that JI-017 so effectively suppressed downstream inflammatory mediators, the team expected to find reduced phosphorylation of the upstream signaling proteins ERK, JNK, NF-κB, and IκB. Instead, under the experimental conditions examined, co-treatment with JI-017 did not reduce LPS-induced phosphorylation of any of these proteins. The authors are careful to note that different LPS concentrations were used across the various assays and that these results do not establish a MAPK- or NF-κB-independent mechanism. But the disconnect between intact upstream signaling and suppressed downstream output is genuinely puzzling, and it raises the possibility that the formulation acts at a level that standard phosphorylation readouts do not capture, perhaps through transcriptional regulation, chromatin modification, or mRNA stability. Identifying that mechanism is now a central question for follow-up work.

The in vivo experiments provided the study’s most clinically resonant results. Male C57BL/6 mice received an intraperitoneal injection of JI-017 at 12.5 milligrams per kilogram one hour before a lethal dose of LPS at 20 milligrams per kilogram, with dexamethasone at 5 milligrams per kilogram serving as a positive control. Over 96 hours of monitoring, Kaplan-Meier survival analysis across all five experimental groups yielded a highly significant overall log-rank statistic of 39.86 with four degrees of freedom and a p value below 0.0001, and the JI-017-treated group was associated with improved survival relative to the LPS-only animals. Twenty-four hours after the LPS challenge, serum levels of IL-1β, IL-6, IFN-γ, CXCL-1, and CXCL-2 were all significantly lower in the JI-017 group, and liver tissue showed reduced mRNA expression of IL-1β, IL-6, CXCL-1, and CXCL-2. Descriptive histopathological examination of hematoxylin and eosin-stained liver sections indicated less prominent tissue damage and inflammation in the JI-017 and dexamethasone groups compared with the LPS-only group, while mice receiving JI-017 alone showed no obvious abnormalities.

The translational logic behind the study is worth emphasizing. Current anti-inflammatory therapies for sepsis, including corticosteroids, work by broadly suppressing immune signaling, which can leave patients vulnerable to secondary infections and impaired pathogen clearance. Excessive inhibition of upstream inflammatory pathways has been repeatedly linked to sepsis-induced immunosuppression. A formulation that reduces inflammatory mediator output without measurably blunting MAPK and NF-κB activation could, in principle, offer a gentler modulation of the inflammatory response, though the authors stress that this possibility remains speculative until the mechanism is defined and immune function during infection is directly tested.

The limitations of the work are candidly acknowledged and considerable. The LPS-induced endotoxemia model captures an acute inflammatory response to bacterial cell wall components but does not reproduce the infectious, polymicrobial complexity of clinical sepsis. The serum ELISA and liver qPCR analyses rested on only three samples per group after exclusions, the histopathological observations were exploratory and unblinded, and batch-specific quality-control documentation for the JI-017 formulation was not available, limiting assessment of its chemical standardization. The in vivo dose was selected from a single preliminary survival experiment without dose-response, pharmacokinetic, or exposure analyses. Even so, the convergence of network pharmacology, cellular evidence, and survival data paints a coherent preliminary picture: a centuries-informed herbal combination, rigorously tested with modern tools, may hold therapeutic value for one of medicine’s deadliest syndromes. The authors call for dose-response, pharmacokinetic, safety, and infection-based sepsis studies as the necessary next steps before JI-017 can be considered a serious candidate for clinical translation.

Subject of Research: Anti-inflammatory effects of the multi-herbal formulation JI-017 in macrophages and an LPS-induced endotoxemia model

Article Title: Anti-inflammatory effects of JI-017 in cellular and an LPS-induced endotoxemia model

Article References: Kim, Y.-H., Lee, S.-E., Choi, G.-E., Kim, D.-E., Cheon, C.-H., & Ko, S.-G. (2026). Anti-inflammatory effects of JI-017 in cellular and an LPS-induced endotoxemia model. Molecular Biology Reports, 53(1), Article 1693. https://doi.org/10.1007/s11033-026-12864-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12864-x

Keywords: sepsis, JI-017, herbal formulation, inflammation, macrophages, lipopolysaccharide, endotoxemia, NF-kB, MAPK, cytokines, Toll-like receptor signaling, natural products